ITALFARMACO SPA Patent applications |
Patent application number | Title | Published |
20140039059 | USE OF HISTONE DEACETYLASE INHIBITORS FOR THE CARE OF PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE SYNDROMES - The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient. | 02-06-2014 |
20130102529 | IRON (III) CASEINSUCCINYLATE AND METHOD FOR THE PREPARATION THEREOF - The present invention refers to an iron (III) caseinsuccinylate characterised by a content of iron comprised between 4.5% and 7% by weight, and by a solubility in water approximately greater than 92%. | 04-25-2013 |
20120039953 | RILUZOLE AQUEOUS SUSPENSIONS - Physically and chemically stable aqueous suspensions of riluzole are disclosed together with the manufacturing methods thereof. Such aqueous suspensions comprise riluzole in particle form and at least a wetting agent, preferably a surfactant. Riluzole is in amounts from about 0.1% to about 20% w/v and has an average particle size lower than 200 μm; such suspensions are devoid of the known local (mouth) anaesthetic effects of riluzole. | 02-16-2012 |
20110237663 | Method for treating Philadelphia-negative myeloproliferative syndromes - A method for treating Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof, in combination with N-hydroxyurea to a patient in need of such a treatment, is described. The diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride in combination with N-hydroxyurea induces positive therapeutic responses in patients refractory to the N-hydroxyurea monotherapy and/or whose therapeutic response to monotherapy with the same dose of N-hydroxyurea is unsatisfactory. | 09-29-2011 |